{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:46:05Z","timestamp":1785321965111,"version":"3.55.0"},"reference-count":32,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.1080\/10428194.2024.2313628","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T06:37:31Z","timestamp":1707806251000},"page":"660-668","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma"],"prefix":"10.1080","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6366-9178","authenticated-orcid":false,"given":"Isha","family":"Mol","sequence":"first","affiliation":[{"name":"Cytel, Inc., Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Hu","sequence":"additional","affiliation":[{"name":"Cytel, Inc., Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-598X","authenticated-orcid":false,"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Aydin","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3332-0180","authenticated-orcid":false,"given":"Alex","family":"Schepart","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Cancer Research UK. Multiple myeloma; 2020 Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/myeloma\/about"},{"issue":"2","key":"e_1_3_5_3_1","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et\u00a0al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.","journal-title":"Hemasphere"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_3_5_6_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Multiple Myeloma Version 3.2023. November 23 2022. (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf)."},{"issue":"1","key":"e_1_3_5_7_1","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala SA","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et\u00a0al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3.","journal-title":"Med Sci"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_5_13_1","unstructured":"Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. (https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma)"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2236303"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02551-9"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05058-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_18_1","unstructured":"European Medicines Agency. Summary of Product Characteristics: Nexpovio. Amsterdam: May 27 2021. (https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio)"},{"key":"e_1_3_5_19_1","unstructured":"European Medicines Agency. Summary of Product Characteristics: Abecma. Amsterdam: August 25 2021. (https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abecma)"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184088"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1511"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0271-1"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970420.62475.d0"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_27_1","first-page":"82","volume-title":"NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit","author":"Phillippo D","year":"2016","unstructured":"Phillippo D, Ades T, Dias S, et\u00a0al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit. Sheffield: University of Sheffield; 2016. p. 82."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10824-3"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2313628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:58:23Z","timestamp":1714139903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2313628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4,15]]}},"alternative-id":["10.1080\/10428194.2024.2313628"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2313628","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}